Rossari Biotech Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ptvdmldqcv8a0jjrs0cdd5xz.pdf

Key Takeaways


The Gross Margin Reset

Sablok: "At the time of IPO and the current scenario, the entire product basket of the company has changed significantly. We didn't have Tristar at that time. We didn't have Unitop at that time. And then we have also gone into some other verticals like paints, paper, and oil and gas. At that time, we had a big account, which you know where the margins were significantly higher, which we don't have anymore."

Working Capital: The 97-Day Question

Chari: "For April and May, Reliance has given us forecast that they will be giving us about 60% of what we normally buy. So, April - May, of course, our capacity will be unutilized to that extent."

HPPC: The Engine and Its Fuel

Sablok: "Our target is to double this in FY25. This business is slightly cash-consuming business in terms of cost as well as in terms of the working capital. But till it reaches a certain size and capacity, it will be a slight push on our working capital position, but that's something we are willingly doing it, because we are quite bullish that the business."

Textile and AHN: The Drags


Exports and New Verticals


Capacity and the FY26 Inflection

Sablok: "But currently, the way we look FY25, we should be a little similar or slightly higher than what we've done in the last year. But in FY26, I think the ramp-up capacities coming in, we should see mid to a slightly higher growth in FY26 and onwards."

Acquisitions: Outperforming the Deal Model

Sablok: "No. I think on the contrary all the acquisitions that we've done has fared much better than what we had planned. Whatever financials we had prepared at the time of acquisition, I think both these have really done much better than that."

Guidance & Commitments

CommitmentSpecificsTimeline
Dahej expansion commissioningCAPEX onstream in phases; revenue bump-up by Q4, major bump-up in FY26Some capacity by end-Q2/early-Q3 FY25; full commissioning by end-FY25
Institutional Cleaning doublingDouble turnover in FY25; double again the following yearFY25 and FY26
Consolidated working capitalBring below 85 days (currently 97 days)No date; prudent to assume 90-day cycle currently
AHN recoveryBounce back with new premix plant and granulation facilityThis year (FY25); machinery commissioning takes 4-6 months
Agro volumesMaintain at FY24 levels based on current order bookFY25
FY25 revenueSimilar or slightly higher than FY24FY25
FY26 revenueMid to slightly higher growth on capacity ramp-upFY26
EBITDA margin base13.5-14% as the base; gradual uptick expected, not returning to older run ratesFY25
Ethylene Oxide supply normalizationReliance expansion to support Rossari's expanded capacityLast quarter of this financial year

Key Metrics

MetricQ4 FY24
Revenue₹472.7 crore, +16.3% YoY
HPPC revenue growth~18% YoY
Revenue mixHPPC 73%, Textile 20%, AHN 7%
EBITDA₹63.6 crore, +16.5% YoY, consistent QoQ
PAT₹34.1 crore, +17.8% YoY, steady QoQ
Gross margin~2% lower in Q4; full year steady at 29%
FY24 full-year revenue₹1,830.6 crore, +10.5% YoY
FY24 full-year EBITDA₹249.8 crore, highest annual EBITDA, margin 13.6%
FY24 full-year PAT₹130.7 crore, highest annual PAT
FY25 revenue milestone~₹2,000 crore expected top line
Textile volume growth~5% annualized in FY24; Q4 volumes up ~10% QoQ
Institutional Cleaning FY24 revenue₹159 crore, ~4% EBITDA margin
Institutional Cleaning working capital85–90 days
Unitop Agro/Non-Agro mix50%–50%, shifted from 65%–35% in FY23
Standalone working capital69–70 days
Consolidated working capital97 days closing; target to bring to 90 days, then below 85 days
CAPEX planned₹128-odd crore for ethoxylation expansion and oil & gas molecule
Unitop 3-year CAGR~20%
Tristar 3-year CAGR24%
EBITDA margin outlook13.5%–14%
Ethylene Oxide supply (Apr–May)~60% of normal purchase volume